| Entry |
|
|---|
| Name |
Erlotinib hydrochloride (JAN/USAN);
Tarceva (TN) |
|---|
| Product |
|
|---|
| Generic |
ERLOTINIB (Areva Pharmaceuticals), ERLOTINIB (Cadila Healthcare Limited), ERLOTINIB (Sun Pharmaceutical Industries), ERLOTINIB (Teva Pharmaceuticals USA), ERLOTINIB (Zydus Pharmaceuticals (USA)), ERLOTINIB (Armas Pharmaceuticals), ERLOTINIB (Armas Pharmaceuticals), ERLOTINIB (Armas Pharmaceuticals), ERLOTINIB (Breckenridge Pharmaceutical), ERLOTINIB HYDROCHLORIDE (Mylan Institutional), ERLOTINIB HYDROCHLORIDE (Mylan Pharmaceuticals) |
|---|
| Formula |
C22H23N3O4. HCl
|
|---|
| Exact mass |
429.1455
|
|---|
| Mol weight |
429.8967
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00711): | D04023<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Non-small cell lung cancer (EGFR mutation positive) [DS: H00014] Pancreatic cancer [DS: H00019] |
|---|
| Target |
|
|---|
| Network |
| N10005 | First/second-generation tyrosine kinase inhibitor to EGFR mutation |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB02 Erlotinib
D04023 Erlotinib hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Erlotinib
D04023 Erlotinib hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D04023 Erlotinib hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D04023 Erlotinib hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04023
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04023
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04023
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04023
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04023
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D04023
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 C8x C 22.3300 -16.9400
2 N5x N 22.3300 -18.3400
3 C8y C 23.5900 -19.0400
4 C8y C 24.7800 -18.3400
5 C8y C 24.7800 -16.9400
6 N5x N 23.5900 -16.2400
7 C8x C 25.9700 -19.0400
8 C8y C 27.1600 -18.3400
9 C8y C 27.1600 -16.9400
10 C8x C 25.9700 -16.2400
11 N1b N 23.5900 -20.3700
12 C8y C 24.7800 -21.0700
13 C8x C 24.7800 -22.4700
14 C8x C 25.9700 -23.1700
15 C8y C 27.1600 -22.4700
16 C8x C 27.1600 -21.0700
17 C8x C 25.9700 -20.3700
18 C3b C 28.3753 -23.1651
19 C3a C 29.5877 -23.8651
20 O2a O 28.3724 -16.2400
21 C1b C 29.5849 -16.9400
22 C1b C 30.7973 -16.2400
23 O2a O 32.0097 -16.9400
24 C1a C 33.2222 -16.2400
25 O2a O 28.3724 -19.0400
26 C1b C 29.5849 -18.3400
27 C1b C 30.7973 -19.0400
28 O2a O 32.0097 -18.3400
29 C1a C 33.2222 -19.0400
30 X Cl 38.7100 -19.5300
BOND 31
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 2
8 7 8 1
9 8 9 2
10 9 10 1
11 5 10 2
12 3 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 15 18 1
21 18 19 3
22 9 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 23 24 1
27 8 25 1
28 25 26 1
29 26 27 1
30 27 28 1
31 28 29 1
|
|---|
